FDA nods spotlight precision oncology platforms as market surges towards $212 billion by 2034

The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes

Bayer and Aignostics to collaborate on next generation precision oncology

Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development

Xyall and Indica Labs forge collaboration to transform precision oncology workflows

Bridging the gap between histopathology and molecular pathology

Crosscope and Farcast Biosciences join efforts to reshape the precision oncology landscape

The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer

Lunit SCOPE matches pathologist accuracy in HER2 scoring for advanced biliary tract cancer

Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology

Zydus signs exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India

Godavari Biorefineries launches US biotech arm to advance novel cancer therapies

The move strengthens GBL’s clinical-stage presence in the United States

Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection

Abbott to acquire Exact Sciences for $21 billion

Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology